L-Glutamine 研究方向
这个分子为什么有研究文献
L-谷氨酰胺是人体血浆与骨骼肌中含量最高的游离氨基酸,兼具氮载体、快速分裂细胞燃料以及细胞培养基底物等角色。它通常被描述为「条件必需」——即正常状态下内源合成被认为足够,但在分解代谢应激时可能不足。这一定位催生了危重症领域大规模的临床研究计划,而该领域关键试验的结果并不符合原假设的预测;正因如此,这支文献值得逐项细读,而不宜只看结论摘要。
文献研究了哪些方向
危重症试验及其实际结果
两项大型随机试验界定了这一领域。Heyland 等(2013)在 New England Journal of Medicine 报告:40 家 ICU 中 1,223 名接受机械通气的多器官衰竭成人被随机分配至谷氨酰胺、抗氧化剂、两者联用或安慰剂组,经静脉与肠内两条途径给药。试验报告谷氨酰胺组 28 天死亡率有升高趋势(32.4% 对 27.2%;校正比值比 1.28),院内与 6 个月死亡率显著更高,而对器官衰竭或感染并发症无影响。Andrews 等(2011)在 BMJ 报告:502 名危重成人被随机分配至肠外谷氨酰胺(20.2 g/日)、硒或两者联用,意向性分析中谷氨酰胺对新发感染与 6 个月死亡率均无影响。这些结果特定于危重人群的肠外及高剂量给药情形,不能直接外推到健康成人的口服补充;但它们是谷氨酰胺文献中样本量最大、检验效能最好的数据。
免疫细胞代谢与「血浆耗竭」假说
谷氨酰胺的机制依据建立在细胞代谢之上。Cruzat 等(2018)在 Nutrients 综述谷氨酰胺代谢,报告免疫细胞对谷氨酰胺的消耗速率与葡萄糖相当甚至更高,其可利用度主要由关键代谢器官调控。Walsh 等(1998)在 Sports Medicine 综述运动免疫学这一分支,报告耐力赛事与长时间运动后血浆谷氨酰胺下降(正常空腹范围为 500-750 µmol/L),而短时高强度运动后则不变或短暂升高;并指出出现过度训练综合征的运动员静息血浆谷氨酰胺低于活跃对照者。该综述同时指出,关于血浆谷氨酰胺作为标志物的最佳测定方法尚未形成共识。这是一支观察性与机制性文献:它确立的是应激下谷氨酰胺通量会改变,而非「补充可纠正某种缺乏」。
肠道通透性试验
Abbasi 等(2024)在 Amino Acids 发表系统综述与荟萃分析,涵盖 1998 至 2014 年间的 10 项临床试验、352 名健康状况各异的受试者,全部为口服给药。总体上,补充谷氨酰胺对肠道通透性无显著影响(加权均数差 -0.00,95% CI -0.04 至 0.03)。剂量高于 30 g/日的亚组分析出现显著下降,但相关试验数量少且人群异质。作者呼吁在不同剂量与患者人群中开展进一步研究。对配方人员而言,关键细节在于:出现亚组信号的剂量远高于常规恢复类粉剂的投料量,而在常规剂量区间内的合并结果为阴性。
运动营养试验与摄入上限考量
Ramezani Ahmadi 等(2019)在 Clinical Nutrition 发表系统综述与荟萃分析,评估运动员补充谷氨酰胺对体重、瘦体重、体脂百分比、最大摄氧量以及淋巴细胞、白细胞和中性粒细胞计数的影响。在单项试验层面,Legault、Bagnall 与 Kimmerly(2015)在 16 名受试者中开展双盲随机安慰剂对照交叉试验,在单侧膝伸离心运动后按 0.3 g/kg/日给药 72 小时,报告 180°/秒下相对峰值力矩高于等能量安慰剂、酸痛评分更低,且男性差异大于女性——这是一项 16 人的交叉试验,属提示性而非结论性结果。在摄入上限方面,Holeček(2022)综述氨基酸补充剂的副作用,讨论了氨的生成以及对共用膜转运载体的竞争,作为与单一氨基酸高摄入相关的机制。
这些文献对你定规格意味着什么
该文献中的口服剂量跨度很大:恢复类研究约 0.3 g/kg/日,肠道通透性亚组高于 30 g/日,危重症肠外给药为 20.2 g/日。跨度如此之大意味着:在把某个已发表方案视为与消费品相关之前,必须先在给药途径与剂量上对齐。从原料角度看,谷氨酰胺水溶性中等,且在水相体系中的稳定性低于多数游离氨基酸,因此即饮与热加工剂型需要做干混剂型所不需要的稳定性验证;同时 FCC 规格应与目标市场自身的食品添加剂法规框架逐条核对。
引用文献
仅为研究背景。以下每一条描述的是某项已发表研究考察了什么、报告了什么,不构成对本原料的宣称,也不构成对任何成品的宣称。法规与标签口径应由把产品投放市场的品牌方自行判断。
- A blinded 2-by-2 factorial randomised trial in 1,223 critically ill adults with multiorgan failure across forty ICUs reported a trend toward increased 28-day mortality with glutamine (32.4% vs 27.2%; adjusted odds ratio 1.28), significantly higher in-hospital and six-month mortality in the glutamine arm, and no effect on organ failure or infectious complications. Heyland D, Muscedere J, Wischmeyer PE, et al. N Engl J Med. 2013;368(16):1489-1497. PMID 23594003DOI 10.1056/NEJMoa1212722
- A randomised double-blind factorial trial in 502 critically ill adults receiving parenteral nutrition reported no overall effect of parenteral glutamine (20.2 g/day) on new infections or six-month mortality in the intention-to-treat analysis. Andrews PJ, Avenell A, Noble DW, et al. BMJ. 2011;342:d1542. PMID 21415104DOI 10.1136/bmj.d1542
- A review of glutamine metabolism reported that the rate of glutamine consumption by immune cells is similar to or greater than that of glucose, and that glutamine availability is controlled mainly by key metabolic organs. Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P. Nutrients. 2018;10(11):1564. PMID 30360490DOI 10.3390/nu10111564
- A review of glutamine, exercise and immune function reported that plasma glutamine (normal fasted range 500-750 µmol/L) falls after endurance events and prolonged exercise but is unchanged or temporarily elevated after short-term high-intensity exercise, that athletes with overtraining syndrome showed lower resting plasma glutamine than active controls, and that no consensus existed on the best method of determining plasma glutamine as a marker. Walsh NP, Blannin AK, Robson PJ, Gleeson M. Sports Med. 1998;26(3):177-191. PMID 9802174DOI 10.2165/00007256-199826030-00004
- A systematic review and meta-analysis of ten clinical trials (352 participants, all oral administration) reported that glutamine supplementation did not significantly affect intestinal permeability overall (weighted mean difference -0.00, 95% CI -0.04 to 0.03), with a significant reduction appearing only in a subgroup analysis of doses above 30 g/day. Abbasi F, Haghighat Lari MM, Khosravi GR, Mansouri E, Payandeh N, Milajerdi A. Amino Acids. 2024;56(1):60. PMID 39397201DOI 10.1007/s00726-024-03420-7
- A systematic review and meta-analysis of clinical trials in athletes assessed glutamine supplementation against body mass, lean body mass, body-fat percentage, VO2max and lymphocyte, leukocyte and neutrophil counts. Ramezani Ahmadi A, Rayyani E, Bahreini M, Mansoori A. Clin Nutr. 2019;38(3):1076-1091. PMID 29784526DOI 10.1016/j.clnu.2018.05.001
- In a double-blind randomised placebo-controlled crossover study in sixteen participants, 0.3 g/kg/day of oral L-glutamine over 72 hours after unilateral knee-extension eccentric exercise was associated with greater relative peak torque at 180°/s and lower muscle soreness ratings at 24, 48 and 72 hours than isoenergetic placebo, with a larger difference reported in men than women. Legault Z, Bagnall N, Kimmerly DS. Int J Sport Nutr Exerc Metab. 2015;25(5):417-426. PMID 25811544DOI 10.1123/ijsnem.2014-0209
- A review of the side effects of amino acid supplements examined glutamine among other amino acids and discussed ammonia production and competition for shared membrane carriers as mechanisms relevant to high intakes. Holeček M. Physiol Res. 2022;71(1):29-45. PMID 35043647DOI 10.33549/physiolres.934790
需要这个等级用于你的产线?
仅为研究背景。以下每一条描述的是某项已发表研究考察了什么、报告了什么,不构成对本原料的宣称,也不构成对任何成品的宣称。法规与标签口径应由把产品投放市场的品牌方自行判断。